Overview:
Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is an increasingly recognized inflammatory demyelinating disorder with distinct clinical, radiographic, and immunologic features. Accurate and timely detection is essential, as diagnostic uncertainty can delay appropriate management and expose patients to ineffective or harmful therapies. This satellite symposium is designed for neurologists seeking practical guidance on identifying MOGAD in clinical practice.
The symposium features experienced clinical experts who will share data and expert commentary drawn from years of treating patients with MOGAD. Faculty will focus on when to suspect MOGAD, how to interpret clinical presentations across age groups, and the optimal use and limitations of serum MOG-IgG testing, including assay selection and result interpretation. Key imaging and differential diagnostic considerations will also be discussed to help distinguish MOGAD from multiple sclerosis, AQP4-positive NMOSD, and other mimics.
Through expert-led
discussion and real-world insights, this program aims to strengthen
neurologists’ confidence in recognizing and confirming MOGAD, supporting
earlier diagnosis and more informed clinical decision-making.
Learning Objectives:
Upon completion of this activity, learners should be able to:
- Describe the burden of disease of MOGAD
- Identify the differential diagnosis for MOGAD
- Implement diagnostic criteria to differentiate MOGAD from other similar disorders